Long-term treatment of rheumatoid arthritis with fenclofenac or gold: a controlled, single blind trial comparing clinical and biochemical parameters.
A randomized parallel group study to compare the effects of fenclofenac and gold was carried out in 35 patients with active rheumatoid arthritis. Patients were treated with either 1200 mg fenclofenac per day or gold in standard doses in addition to their non-steroidal anti-inflammatory therapy and monitored for up to twelve months. The two treatments produced similar improvements in erythrocyte sedimentation rate, orosomucoid and haptoglobin. In addition, gold produced improvements in haemoglobin, IgG and alpha 1-antitrypsin, but there were no statistically significant differences between the clinical responses. Fenclofenac caused significantly fewer and less serious unwanted effects.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D001798:Blood Proteins / Q000032:analysis; D001799:Blood Sedimentation; D002986:Clinical Trials as Topic; D005260:Female; D006046:Gold / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010648:Phenylacetates / Q000009:adverse effects / Q000627:therapeutic use*; D011897:Random Allocation
D000893:Anti-Inflammatory Agents; D001798:Blood Proteins; D010648:Phenylacetates; D006046:Gold; C012970:fenclofenac